REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to beat relapsed blood cancers
Disease control Recruiting nowThis study tests a new approach for adults with blood cancers like AML that have come back or not responded to treatment. Participants receive intense chemotherapy followed immediately by a donor stem cell transplant, plus drugs to prevent graft-versus-host disease. The goal is t…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
New combo therapy aims to boost leukemia treatment
Disease control Recruiting nowThis study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will take…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Radioactive antibody targets leukemia before transplant
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk acute leukemias or myelodysplastic syndrome. The antibody seeks out and delivers radiation to cancer cells while sparing healthy cells. The goal is to find …
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New combo therapy aims to stop relapse in tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for adults with aggressive blood cancers like acute myeloid leukemia (AML) that are hard to cure. Patients receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) and total body radiation, followed by a stem cell transplant from a h…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Radioactive antibody blasts cancer before stem cell rescue in High-Risk leukemia trial
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The antibody targets cancer cells and delivers radiation, then c…
Matched conditions: REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC